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Summary
A number of independent lines of evidence converge indicating a role for nitric oxide (NO) in angiogenesis. Our data support the existence
of an autocrine loop exerted by microvascular endothelium in angiogenesis which involves NO production, cyclic GMP elevation and
fibroblast growth factor-2 (FGF-2) expression. Our results indicate that NO production significantly contributes to the growth-promoting effect
of vasodilating peptides and vascular endothelial growth factor (VEGF), but not for that of FGF-2. On these basis, the nitric oxide pathway
appears to be a promising target to be considered in pro- and anti-angiogenic therapeutic strategies.
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The occurrence of neovascularization in the articular carti-
lage represents a major problem in the evolution of the
inflammatory process affecting joints. Therapeutic interven-
tion in rheumatological diseases as well as for other
angiogenesis dependent diseases is thus the block of
pathological angiogenesis. The comprehension of the
mechanism underlying the angiogenesis process and the
characterization of the molecules involved, is instrumental
for the development of antiangiogenic strategies.
In order to study angiogenesis we have focused our
effort in monitoring the vascularization process occurring in
avascular tissue, i.e., the cornea of albino rabbits. The
cornea assay respect to the other in-vivo assays, has
the advantage of measuring only new blood vessels, since
the cornea is initially avascular.
The steps required for new vessel growth are biologically
complex and require co-ordinate regulation of contributing
components, including modifications of cell–cell inter-
actions, proliferation and migration of endothelial cells and
matrix degradation involving urokinase-type plasminogen
activator (uPA).1 The observation that in-vivo angiogenesis
is accompanied by vasodilation and that many angio-
genesis effectors possess vasodilating properties,
prompted us to search for evidence of a molecular/
biochemical link between vasodilation and angiogenesis.
Indeed both events occur under a strict control exerted
by the endothelial cells on the surrounding cellular
components.
Endothelium-dependent relaxation is known to arise
from endothelium derived nitric oxide (NO) inducing cyclic
GMP (cGMP) in the vascular smooth muscle cell.2 The
synthesis of NO by endothelial cells can be blocked by
L-arginine analogs such as Nw-mono-methyl-L-arginine
(L-NMMA) and Lw-nitro-L-arginine methyl ester (L-NAME),
while D-isomers are ineffective.
Three experimental observations attracted our attention
to study the role of NO in angiogenesis. First, in experi-
mental models where angiogenesis can be directly
monitored, vasodilation and hyperemia of the pre-existing
capillaries and the persistence of a dilation state of the403newly formed vessels are typical findings.3 Second, several
angiogenesis factors/mediators promote relaxation in
vascular preparations and peptides known to induced
endothelium-mediated vasorelaxation are angiogenic.4,5
Third, persistent vasodilation is a specific feature in tumor
vasculature and in the surrounding tissue. Furthermore in
studying endothelium dependent vasodilating peptides we
demonstrated a role for NO in angiogenesis.ResultsTHE NO/CGMP PATHWAY IN ANGIOGENESIS
Several reports have implicated a role for NO synthase
in angiogenesis. For example, it was shown that angio-
genic activity was only released from bacterial endotoxin
treated human monocytes in the presence of L-arginine.6
More recently the role of NO in mediating the angiogenic
activity elicited by different cytokines has been described.7
Similarly L-Arginine was shown to favour healing and
angiogenesis in gastric ulcerations while NO synthase
inhibitors delayed it.8 To assess the role of NO in angio-
genesis we investigated whether NO could act as an
angiogenesis effector per se and as a modulator of the
activity and/or the production of angiogenesis factors. The
relevance of NO in angiogenesis was assessed in vitro by
testing the activity of NO producing agents on the cellular
events of angiogenesis in cultured capillary endothelium,
and in vivo in rabbit corneas receiving angiogenesis effec-
tor and tumor cell implant during systemic treatment with
NO-synthase inhibitors.
Following this approach we could demonstrate that
chemical mediators which activate the constitutive NO
synthase, like substance P (SP) as well as NO donors,
such as sodium nitroprusside (NaNP), promoted endo-
thelial cell proliferation and migration in vivo and in vitro,
while inhibitors of NO synthase suppressed these
responses.9 The growth promoting effect of NO appeared
to be linked to cGMP generation in cultured endothelium,10
suggesting the existence of an autocrine/paracrine loop in
NO effect. In vivo, NO synthase inhibitors suppress angio-
genesis induced by vasodilating effectors like SP and
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9induced by fibroblast growth factor-2 (FGF-2).THE MECHANISM UNDERLYING NO-INDUCED ANGIOGENESIS
INVOLVES ENDOGENOUS FGF-2 PRODUCTION
The mechanism by which NO controls angiogenesis was
not completely clarified. A possible explanation was that
NO could modulate the activity and/or the production of
angiogenesis factors as indicated for other peptides.11
Fibroblast growth factor-2 (FGF-2) is a potent angiogenesis
factor and in vitro studies have demonstrated that
FGF-2 can initiate the cellular responses associated with
angiogenesis including uPA production and cell division in
autocrine fashion.1,12
In order to elucidate the mechanism of action of NO in
angiogenesis, we investigated the interaction of NO and
FGF-2 in signalling proliferation and uPA production in
vascular endothelium. In postcapillary venular endothelial
cells we found that dose-dependent increase in uPA activity
paralleled DNA synthesis in response to FGF-2 and to the
NO-donor drug NaNP. Neutralizing anti-FGF-2 antibodies
blocked uPA production and DNA synthesis following
nipride treatment. Similar results were obtained when
increase in NO levels were produced by the use of SP.
Endothelial cells exhibited increased expression of mRNA
and protein of FGF-2 and the proliferation induced by SP
was blocked by anti-FGF-2 antibodies and by NO synthase
inhibitors. Thus NO, both exogenous and endogenous,
induced the endothelial cells to produce FGF-2 and to
respond to the endogenous growth factor revealing a
feedback loop between vasodilation and angiogenesis
13controlled by the endothelium via NO and FGF-2.VEGF, NO AND ANGIOGENESIS
To then assess the role of NO in tumor angiogenesis we
investigated whether the L-arginine/NO pathway partici-
pated to vascular endothelial growth factor (VEGF) and
FGF-2 activity. VEGF is a secreted endothelial-specific
growth factor that is strongly angiogenic in vivo.14 More-
over, VEGF effects on permeability and vascular tone are
coupled to nitric oxide production.15 We started by investi-
gating whether the NO pathway participated in VEGF
activity. We found that NO production significantly contrib-
uted to the growth-promoting effect of VEGF, but not for
that of FGF-2.16 Postcapillary endothelial cell mobilization,
adhesion and growth induced by VEGF were blocked by
the NO synthase inhibitor L-NMMA and by the guanylate
cyclase inhibitor LY 83583, while these inhibitors did not
modify FGF-2 effects. VEGF effect appears to be selec-
tively linked to the NO pathway. In fact, L-NAME, but not
D-NAME, completely blocked neovascularization induced
by the VEGF transfectants, while the cells remained
dormant in the cornea. Consistently, VEGF induced angio-
genesis was inhibited by NO synthase inhibitors while the
angiogenic activity of FGF-2 was not affected. Thus, nitric
oxide appeared to be a downstream imperative of VEGF
17but not FGF-2 induced angiogenesis.Conclusions
In microvascular endothelium, NO production signifi-
cantly contributes for the growth-promoting effect of vaso-
dilating peptides and VEGF, but not for that of FGF-2. Thespecificity of the NO synthase inhibitors on VEGF induced
angiogenesis and not FGF-2 induced angiogenesis pro-
vides new evidence for the existence of the two angiogenic
pathways. Thus, although the NO pathway integrates
several chemical and physical modulators of the angio-
genic process, not all angiogenic factors depend on this
signalling cascade. This highlights the problem that arises
as a result of the fact that angiogenesis involves multiple
factors, namely, that blocking of any single angiogenic
factor is unlikely to be an effective antiangiogenic
strategy. More work with specific inhibitors of the NO
synthase isoforms is needed nevertheless the nitric oxide
pathway stays as a promising target for consideration in
anti-angiogenic therapeutical strategies.Acknowledgments
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